RT Journal Article
SR Electronic
T1 COMPARATIVE IMMUNOGENICITY OF BNT162b2 mRNA VACCINE WITH NATURAL COVID-19 INFECTION
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.15.21258669
DO 10.1101/2021.06.15.21258669
A1 Mina Psichogiou
A1 Andreas Karabinis
A1 Garyphallia Poulakou
A1 Anastasia Antoniadou
A1 Anastasia Kotanidou
A1 Dimitrios Degiannis
A1 Ioanna D. Pavlopoulou
A1 Antigoni Chaidaroglou
A1 Sotirios Roussos
A1 Elpida Mastrogianni
A1 Irene Eliadi
A1 Dimitrios Basoulis
A1 Konstantinos Petsios
A1 Konstantinos Leontis
A1 Eleni Kakkalou
A1 Konstantinos Protopapas
A1 Edison Jahaj
A1 Maria Pratikaki
A1 Konstantinos N. Syrigos
A1 Pagona Lagiou
A1 Helen Gogas
A1 Sotirios Tsiodras
A1 Gkikas Magiorkinis
A1 Dimitrios Paraskevis
A1 Vana Sypsa
A1 Angelos Hatzakis
YR 2021
UL http://medrxiv.org/content/early/2021/06/21/2021.06.15.21258669.abstract
AB The mRNA vaccine BNT162b2 has proven highly effective and currently many millions are being vaccinated. There are limited and conflicting data from immunogenicity studies on the effects of age, gender, vaccination side effects (VSE), risk factors for severe COVID-19 (RFS-COV), obesity (BMI) and previous SARS-CoV-2 (Pr-CoV) Moreover, immunogenicity data from COVID-19 patients comparing various disease categories of natural infection i.e. asymptomatic vs mild vs moderate vs severe infection are sparse, and include limited number of individuals.This study included 871 vaccinated health care workers (HCW) and 181 patients with natural infection. Immunogenicity was assessed by a quantative assay measuring anti-SARS-CoV-2 against the RBD domain of the spike protein (anti-RBD) and anti-SARS-CoV-2 against nucleocapsid protein (anti-N). Samples were collected 1-2 weeks after completion of the 2nd dose in the vaccinated HCWs and 15-59 days post symptoms onset in patients with natural infection.The concentration of anti-RBD in vaccinated individuals after multivariable analysis was significantly associated with age, gender, VSE and Pr-CoV. Specifically, anti-RBD median levels (95% CI) were lower by 2,466 (651-5,583), 6,228 (3,254-9,203) and 7,651 (4,479-10,823) AU/ml in 35-44, 45-54, 55-70 yrs respectively, compared with 18-34 yrs group. In females, median levels of anti-RBD were higher by 2,823 (859-4,787) compared with males, in individuals with VSE were higher by 5,024 (3,122-6,926) compared with no VSE, and in HCWs with Pr-CoV were higher by 9,971 (5,158-14,783) AU/ml compared with HCWs without Pr-CoV.Among individuals with natural infection, the median anti-RBD levels were 14.8 times higher in patients with critical COVID-19 infection compared with non-hospitalized individuals. The ratio of anti-RBD in vaccinated individuals versus those with natural infection varied from 1.0 up to 19.4 according to the clinical subgroup of natural infection.This study proves the high immunogenicity of BNT162b2 vaccine although its sustainability remains to be seen. The use of comparative data from natural infection serological panels, expressing the clinical heterogeneity of natural infection may facilitate early decisions for vaccine evaluation in clinical trials.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by: Onassis Cardiac Surgery Center Union of Greek Ship Owners SB Bioanalytica S.A. Hellenic Scientific Society for the Study of AIDS, Sexually Transmitted and Emerging DiseasesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the IRB committees of Laiko General Hospital and Onasis Cardiac Surgery Center.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesA limited data set is available for sharing upon request after the acceptance of the manuscript